# A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

> **NCT07196644** · PHASE2 · RECRUITING · sponsor: **AbbVie** · enrollment: 125 (estimated)

## Conditions studied

- Solid Tumors Harboring MET Amplification

## Interventions

- **DRUG:** Telisotuzumab Adizutecan

## Key facts

- **NCT ID:** NCT07196644
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-29
- **Primary completion:** 2030-12
- **Final completion:** 2030-12
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07196644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07196644, "A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07196644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*